Abstract
The importance of adequate provision for expert statistical review of license applications by European regulatory agencies has been increased by several developments including moves toward international harmonization. A brief questionnaire on the roles of statisticians and statistical review procedures was sent to the director of the national drug regulatory agency in each of 18 European countries (current and prospective members of the European Union [EU] and other related countries). The topics covered included: 1. The number of statisticians employed by the authority or used as advisers, and the extent of this use, 2. Which license applications are statistically reviewed, how these are selected, and which parts of applications are considered, and 3. The potential impact of the setting up of the European Medicines Evaluation Agency and adoption of the EU Note for Guidance on Biostatistical Methodology in Clinical Trials.
Of the 14 full responders, three (Sweden, German, and the United Kingdom) reported employing professional statisticians to review license applications and/or clinical trial protocols. In most countries only selected license applications are reviewed statistically, selected on statistical complexity by nonstatistical assessors. There are some restrictions on discussion of applications/protocols with statisticians working for the sponsors. As a result of adoption of the EU Biostatistical guidelines, Germany intends to employ more statisticians and the possibility is under consideration in The Netherlands, Greece, and Switzerland. Almost all of the remaining responders report that they do not intend to employ (more) statisticians. Austria, Belgium, Denmark, Ireland, and Finland, however, are proposing to make more use of statistical advisers. International harmonization may be impeded by the evident range of resource provision and procedures within Europe.
Similar content being viewed by others
References
Royal Statistical Society Working Party on Statistics in Drug Regulation. Statistics and statisticians in drug regulation in the United Kingdom. J Roy Stat Soc A. 1992;154:413–419.
Lewis JA. Editorial: Statistics and statisticians in the Regulation of Medicines. J Roy Stat Soc A. 1996; 159: 359–362.
Griffin JP, Charlesworth FA. European procedures for obtaining marketing authorizations for human medicines after 1992-−EC commission proposals. Int Pharmacy J. 1990;4:246–251.
Committee on Proprietary Medicinal Products Working Party on Efficacy of Medicinal Products. Note for Guidance III/3630/92-EN: Biostatistical Methodology in Clinical Trials in Applications for Marketing Authorizations for Medicinal Products. Brussels: European Commission; 1994.
D’Arcy PF, Harron DWG, eds. Proceedings of the 1st International Conference on Harmonization. Belfast: Queen’s University; 1992.
Jones DR. The future of statistics and statisticians in European regulatory affairs. Control Clin Trials. 1992;13:459–465.
International Conference on Harmonization. Structure and content of clinical study reports. 137/95. London: EuroDirect Publications Offices; 1995.
Author information
Authors and Affiliations
Additional information
On behalf of the International Society for Clinical Biostatistics Working Party on Statistics in European Drug Regulation
Rights and permissions
About this article
Cite this article
Köpcke, W., Jones, D.R., Huitfeldt, B. et al. Statistics and Statisticians in European Drug Regulatory Agencies. Ther Innov Regul Sci 32, 243–251 (1998). https://doi.org/10.1177/009286159803200132
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159803200132